This volume investigates the physiological and biochemical mechanisms of calcium sensitizers as a novel therapeutic strategy for treating heart failure. The authors, David G. Allen and John A. Lee, synthesize current research to explain how these agents enhance cardiac contractility without the adverse effects linked to traditional calcium-elevating drugs. By examining the interaction between calcium and contractile proteins, the text establishes a framework for understanding this shift in clinical pharmacology.

Experts recognize this work as a foundational text for understanding the shift toward calcium sensitization in cardiac therapy. Readers frequently note the technical density of the prose, which is tailored for researchers and clinicians in the field of cardiovascular medicine.